Document is current
Any future updates will be listed below
-
Authors
Mochizuki, Kohei
Higa, Mariko https://orcid.org/0000-0001-9650-7882
Ikehara, Kayoko
Ichijo, Takamasa
Hirose, Takahisa
- License Information
-
More Information
Article History
Received: 26 March 2024
Accepted: 10 September 2024
First Online: 23 November 2024
Declarations
:
: Takahisa Hirose has received honoraria from Sand KK, Eli Lily Japan KK, Novo Nordisk Pharma Ltd, MSD KK, Sumitomo Pharma Co. Ltd, Astra Zeneca KK, Mitsubishi Tanabe Pharma Corporation, Kowa Co. Ltd, Kissei Pharmaceutical Co. Ltd, Abbott Japan LLC, and research funding from Mitsubishi Tanabe Pharma Corporation, and subsidies or donations from Tanabe Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharma Corporation, Sumitomo Pharma Co. Ltd, Novo Nordisk Pharma Ltd, Nippon Boehringer Ingelheim Co. Ltd. Kohei Mochizuki, Mariko Higa, Kayoko Ikehara and Takamasa Ichijo declare no conflict interest associated with this manuscript.
: This study was conducted with Ethics Review Committee of Saiseikai Yokohamashi Tobu Hospital (the approval number 20220148), which was approved on November 22, 2022. All the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and/or with Helsinki Declaration 1964 and later versions. The written informed consent was obtained prior to the study after providing explanations of the purpose of the study.
